‘Stunning results’ for Revolution Medicines pancreatic cancer drug

Adam Feuerstein is a senior author and biotech columnist, reporting on the crossroads of drug improvement, enterprise, Wall Avenue, and biotechnology. He’s additionally a co-host of the weekly biotech podcast The Readout Loud and writer of the e-newsletter Adam’s Biotech Scorecard. You may attain Adam on Sign at stataf.54.

CHICAGO — Rachna Shroff, a doctor and pancreatic most cancers skilled, was seeing sufferers on the College of Arizona Most cancers Middle in April when she heard the hanging medical outcomes about an experimental tablet known as daraxonrasib. Sufferers taking the focused drug lived almost twice so long as sufferers provided normal chemotherapy — an final result by no means seen earlier than within the pancreatic most cancers discipline. 

“Having handled pancreatic most cancers for 16 years, I really began crying within the clinic,” Shroff stated at a media briefing. “That is such an extremely impactful research for our sufferers.”

On Sunday, detailed outcomes from the daraxonrasib medical trial carried out by the drug’s maker, the biotech firm Revolution Medicines, have been introduced right here on the plenary session of the annual assembly of the American Society of Scientific Oncology. The research was revealed concurrently within the New England Journal of Drugs.